These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29851132)

  • 1. Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
    Dewan AK; Sowerby L; Jadeja S; Lian C; Wen P; Brown JR; Fisher DC; LeBoeuf NR
    Clin Exp Dermatol; 2018 Dec; 43(8):890-894. PubMed ID: 29851132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pityriasis rubra pilaris-like reaction induced by imatinib.
    Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
    Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
    Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
    Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
    Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
    Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
    [No Abstract]   [Full Text] [Related]  

  • 5. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.
    Matsuda T; Yamazaki F; Ueda-Hayakawa I; Kambe N; Okamoto H
    J Dermatol; 2019 Jan; 46(1):70-72. PubMed ID: 30506728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pityriasis Rubra Pilaris With Extensive Follicular Acantholysis Resembling Pemphigus Vulgaris: A Case Report.
    Lilo MT; Yan S; Chapman MS; Linos K
    Am J Dermatopathol; 2019 Jan; 41(1):37-39. PubMed ID: 30045068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review.
    Leite OG; Tagliolatto S; Souza EM; Cintra ML
    An Bras Dermatol; 2020; 95(1):63-66. PubMed ID: 31789270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
    Jack A; Mauro MJ; Ehst BD
    J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
    [No Abstract]   [Full Text] [Related]  

  • 9. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features.
    Ko CJ; Milstone LM; Choi J; McNiff JM
    Int J Dermatol; 2011 Dec; 50(12):1480-5. PubMed ID: 22097993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythroderma after corticosteroid withdrawal in papulosquamous dermatosis in children. Diagnosis: pityriasis rubra pilaris, classic juvenile type].
    Terheyden P; Hofmann UB; Hamm H; Bröcker EB
    Hautarzt; 2001 Nov; 52(11):1058-61. PubMed ID: 11757463
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
    Vastarella M; Fabbrocini G; Sibaud V
    Drug Saf; 2020 May; 43(5):395-408. PubMed ID: 31981081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients.
    Montero-Menárguez J; Amat Samaranch V; Puig Sanz L; Ruiz-Villaverde R; Arias-Santiago S; Larrea García M; Ruiz Genao D; Ferrán M; Schneller-Pavelescu L; Romero Ferreiro C; Rivera Díaz R
    Actas Dermosifiliogr; 2024 Sep; 115(8):761-765. PubMed ID: 38401879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of erythrodermic pityriasis rubra pilaris with acitretin.
    Atzori L; Zanniello R; Lappi A; Pinna AL; Ferreli C; Rongioletti F; Pilloni L
    Dermatol Ther; 2018 Sep; 31(5):e12694. PubMed ID: 30230135
    [No Abstract]   [Full Text] [Related]  

  • 14. Pityriasis rubra pilaris: evolution of challenges in promising treatment options.
    Sehgal VN; Srivastava G; Verma P
    Skinmed; 2012; 10(1):18-23. PubMed ID: 22324172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.
    Hunjan MK; Roberts C; Karim S; Hague J
    Clin Exp Dermatol; 2022 Jan; 47(1):188-190. PubMed ID: 34379821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid.
    Genovese G; Muratori S; Berti E; Marzano AV
    Clin Exp Dermatol; 2019 Jan; 44(1):73-75. PubMed ID: 30129048
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs associated with development of pityriasis rubra pilaris: A systematic review.
    Mufti A; Lytvyn Y; Maliyar K; Sachdeva M; Yeung J
    J Am Acad Dermatol; 2021 Apr; 84(4):1071-1081. PubMed ID: 32687965
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
    Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
    Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pityriasis rubra pilaris].
    Artik S; Kuhn A; Neumann NJ; Ruzicka T; Megahed M
    Hautarzt; 2004 Oct; 55(10):980-3. PubMed ID: 15365642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
    Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
    Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.